NTP-CERHR expert panel report on the reproductive and developmental toxicity of amphetamine and methamphetamine

Birth Defects Research Part B - Developmental and Reproductive Toxicology

Volumn 74, Issue 6, 2005, Pages 471-584

  Golub, Mari ^a   Costa, Lucio ^b   Crofton, Kevin ^c   Frank, Deborah ^d   Fried, Peter ^e   Gladen, Beth ^f   Henderson, Rogene ^g   Liebelt, Erica ^h   Lusskin, Shari ⁱ   Marty, Sue ^j   Rowland, Andrew ^k   Scialli, John ^l   Vore, Mary ^f   Shelby, Michael D ^f  

^a CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

^d BOSTON MEDICAL CENTER   (United States)

^e CARLETON UNIVERSITY   (Canada)

^f NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^g LOVELACE RESPIRATORY RESEARCH INSTITUTE   (United States)

^h UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

ⁱ NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j DOW CHEMICAL COMPANY   (United States)

^k UNIVERSITY OF NEW MEXICO   (United States)

^l University of Kentucky ^*

more..

Author keywords

[No Author keywords available]

Indexed keywords

1 (2 HYDROXYPHENYL)ISOPROPYLAMINE; 3,4 METHYLENEDIOXYMETHAMPHETAMINE; 4 HYDROXYPHENYLPROPANOLAMINE; ACEDRON; ADJUDETS; ALCOHOL; ALGODEX; AMDEX; AMDRAM; AMEDRINE; AMPHAETEX; AMPHEDROXY; AMPHETAMINE; AMPHETAMINE DERIVATIVE; ANOREXIDE; ANOREXINE; APETAIN; BARBITURIC ACID DERIVATIVE; BENZOIC ACID; BETAFEDRINE; BIPHTAMINE; BOMBITA; CANNABIS; CARRTIME; CENTRAL STIMULANT AGENT; CHESTOX; COCAINE; CRADEX; CURBAN; D BENZEDRINE; DAMS; DAS; DASDEL; DELLIPSOIDS; DEOXYFED; DEPHADRIN; DEPOXIN; DESEPIN; DESFEDRAN; DESODEX; DESOXEDRIN; DESYFED; DEX OB; DEX SULE; DEXAMINE; DEXAMPHETAMINE; DEXOPHRINE; DEXSTIM; DEXTEN; DEXTENAL; DEXTREX; DEXTROPROFETAMINE; DEXTROSULE; DIPHYLETS; DITAB; DOPAMINE TRANSPORTER; DOPIDRIN; DOSOXY; DURA DEX; EPHADREN; ESKATROL; FENOPROMIN; FENYPRIN; FERNDEX; FINAM; FURAZOLIDONE; HYDROXYAMPHETAMINE; ILLICIT DRUG; KETONE DERIVATIVE; LANAZINE; LENTANET; LEVETAMIN; LIPSOIDS; LOWEDEX; LYSERGIDE; MAXITON SULFATE; MEDEX; MEPHO D; METHAMPHETAMINE; METHEDRINAL; METHYLBENZEDRIN; METHYLPHENIDATE; MILLERDRINE; MONOAMINE OXIDASE INHIBITOR; NEODRINE; NEOPHARMADRINE; NORADRIN; NOREPHEDRINE; NORODRINE; OBESINE; OPIATE; PAREMYD; PELLCAP; PEMOLINE; PERKE; PHEDOXE; PHEDRISOX; PHENAMINE; PHENOTHIAZINE DERIVATIVE; PHOLEDRINE; PRODEXTER; PROMADEX; PROPYLHEXEDRINE; PROTIOAMPHETAMINE; PSICOPAN; PSYCHERGINA; PSYCHERGINE; PSYCHODRINE; RECORDATI; RECREATIONAL DRUG; ROBESE; SIMPATINA; STIMULEX; TEMPODEX; TRANQUILIZER; TUPHETAMINE; TYDEX; TYRAMINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; WECKAMINE; ZAMINE;

ABDOMINAL PAIN; ACCIDENTAL INJURY; AGITATION; ANOREXIA; APPETITE; AREA UNDER THE CURVE; ASTHENIA; ATTENTION DEFICIT DISORDER; AUTOMUTILATION; BRAIN HEMORRHAGE; BRAIN TOXICITY; CARCINOGENICITY; CARDIOMYOPATHY; CARDIOTOXICITY; CEREBROVASCULAR ACCIDENT; CHILD DEATH; CHILD DEVELOPMENT; CHILL; CONGENITAL HEART MALFORMATION; CONSTIPATION; DELCOBESE; DEPRESSION; DIARRHEA; DISEASE EXACERBATION; DISEASE PREDISPOSITION; DIZZINESS; DOSE RESPONSE; DRUG ABSORPTION; DRUG ABUSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG FATALITY; DRUG FORMULATION; DRUG HALF LIFE; DRUG HYDROXYLATION; DRUG INDICATION; DRUG MANUFACTURE; DRUG MECHANISM; DRUG METABOLISM; DRUG OVERDOSE; DRUG PURITY; DRUG SAFETY; DRUG SALIVA LEVEL; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERANCE; DRUG URINE LEVEL; DRUG USE; DYSPEPSIA; EMBRYO DEVELOPMENT; EUPHORIA; EVALUATION; EXPERIMENTAL ANIMAL; FATIGUE; FETUS DEVELOPMENT; FEVER; GASTROINTESTINAL DISEASE; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; GENETIC SUSCEPTIBILITY; GESTATIONAL AGE; GILLES DE LA TOURETTE SYNDROME; GOVERNMENT; HALLUCINATION; HEADACHE; HEART INFARCTION; HEART PALPITATION; HEMOPTYSIS; HUMAN; HYPERTENSION; IMPOTENCE; INFECTION; INSOMNIA; IRRITABILITY; KIDNEY CLEARANCE; LIBIDO DISORDER; LUNG EDEMA; LUNG TOXICITY; MALIGNANT HYPERTHERMIA; MATERNAL WELFARE; MENTAL INSTABILITY; MOTOR DYSFUNCTION; MUTAGENICITY; NARCOLEPSY; NAUSEA; NERVOUSNESS; NONHUMAN; OBEDRIN LA; OBESITY; PERSONALITY DISORDER; PRENATAL EXPOSURE; PRIORITY JOURNAL; PSYCHOSIS; PULMONARY HYPERTENSION; RACEMIZATION; REPRODUCTIVE TOXICITY; RESTLESSNESS; REVIEW; RHABDOMYOLYSIS; SEIZURE; SEXUAL DYSFUNCTION; SHOCK; SIDE EFFECT; SKIN DISEASE; STILLBIRTH; SUSTAINED RELEASE PREPARATION; TACHYCARDIA; TASTE DISORDER; THORAX PAIN; TIC; TISSUE LEVEL; TREMOR; URINARY EXCRETION; URTICARIA; VIRUS INFECTION; VOMITING; WEIGHT REDUCTION; XEROSTOMIA;

AGE FACTORS; AMPHETAMINE; AMPHETAMINE-RELATED DISORDERS; ANIMALS; CHILD; ENVIRONMENTAL EXPOSURE; FEMALE; GROWTH AND DEVELOPMENT; HUMANS; MALE; METHAMPHETAMINE; MUTATION; NERVOUS SYSTEM; PREGNANCY; PROGRAM EVALUATION; REPRODUCTION; SEX FACTORS; SPECIES SPECIFICITY;

ANIMALIA; CANNABIS; DEXAMINE;

EID: 30044450387     PISSN: 15429733     EISSN: None     Source Type: Journal    
DOI: 10.1002/bdrb.20048     Document Type: Review

References (258)

1. AAP. 2001. Clinical practice guideline: treatment of the school-aged child with attention-deficit/hyperactivity disorder. Pediatrics 108:1033-1044.
2. Aarskog D, Ferang F, Klove H, Stoa KF, Thorsen T. 1977. Effect of the stimulant drugs, dextroamphetamine and methylphenidate on secretion of growth hormone in hyperactive children. J Pediatr 90:136-139.
3. Acuff-Smith KD, George M, Lorens SA, Vorhees CV. 1992. Preliminary evidence for methamphetamine-induced behavioral and ocular effects in rat offspring following exposure during early organogenesis. Psychopharmacology (Berl) 109:255-263.
4. Acuff-Smith KD, Schilling MA, Fisher JE, Vorhees CV. 1996. Stage-specific effects of prenatal d-methamphetamine exposure on behavioral and eve development in rats. Neurotoxicol Teratol 18:199-215.
5. Adams J, Buelke-Sam J, Kimmel CA, LaBorde JB. 1982. Behavioral alterations in rats prenatally exposed to low doses of d-amphetamine. Neurobehav Toxicol Teratol 4:63-70.
6. Adams J, Buelke-Sam J, Kimmel CA, Nelson CJ, Reiter LW, Sobotka TJ, Tilson HA, Nelson BK. 1985a. Collaborative Behavioral Teratology Study: protocol design and testing procedures. Neurobehav Toxicol Teratol 7:579-586.
7. Adams J, Oglesby DM, Ozemek HS, Rath J, Kimmel CA, Buelke-Sam J. 1985b. Collaborative Behavioral Teratology Study: programmed data entry and automated test systems. Neurobehav Toxicol Teratol 7:547-554.
8. Ahmann PA, Waltonen SJ, Olson KA, Theye FW, Van Erem AJ, LaPlant RJ. 1993. Placebo-controlled evaluation of Ritalin side effects. Pediatrics 91:1101-1106.
9. Akorn. 2001. Product label on Paremyd. Somerset, NJ: Akorn, Inc.
10. Albertson TE, Derlet RW, Van Hoozen BE. 1999. Methamphetamine and the expanding complications of amphetamines. West J Med 170:214-219.
11. Alcohol and Drug Information Clearing House. 1998. Methamphetamine. Available at http://www.prevlink.org/clearinghouse/catalog/drugs/meth/methbro. pdf. Alcohol and Drug Information Clearing-house and Nebraska Prevention Information Network.
12. Alhava E, Mattila M. 1974. Dose-dependent differences of amphetamine levels in brain and heart of adult and developing mice. Acta Pharmacol Toxicol 34:211-221.
13. Anggard E, Gunne LM, Jonsson LE, Niklasson F. 1970. Pharmcokinetic and clinical studies on amphetamine-dependent subjects. Eur J Clin Pharmacol 3:3-11.
14. Anggard E, Jonsson LE, Hogmark AL, Gunne LM. 1973. Amphetamine metabolism in amphetamine psychosis. Clin Pharmacol Ther 14:870-880.
15. Angrist B, Gershon S. 1976. Clinical effects of amphetamine and L-DOPA on sexuality and aggression. Compr Psychiatry 17:715-722.
16. Anzenbacher P, Anzenbacherova E. 2001. Cytochromes P450 and metabolism of xenobiotics. Cell Mol Life Sci 58:737-747.
17. Barkley RA, Fischer M, Smallish L, Fletcher K. 2003. Does the treatment of attention-deficit/hyperactivity disorder with stimulants contribute to drug use/abuse? A 13-year prospective study. Pediatrics 111:97-109.
18. Bashour TT. 1994. Acute myocardial infarction resulting from amphetamine abuse: a spasm-thrombus interplay? Am Heart J 128:1237-1239.
19. Bays J. 1991. Fetal vascular disruption with prenatal exposure to cocaine or methamphetamine. Pediatrics 87:416-418.
20. Bell RW, Drucker RR, Woodruff AB. 1965. The effects of prenatal injections of adrenalin chloride and D-amphetamine sulfate on subsequent emotionality and ulcer-proneness of offspring. Psychon Sci 2:269-270.
21. Bertilsson L, Dahl ML, Tybring G. 1997. Pharmacogenetics of anti-depressants: clinical aspects. Acta Psychiatr Scand Suppl 391:14-21.
22. Biederman J, Wilens T, Mick E, Spencer T, Faraone SV. 1999. Pharmacotherapy of attention-deficit/hyperactivity disorder reduces risk for substance use disorder. Pediatrics 104:e20.
23. Bigl V, Dalitz E, Kunert E, Biesold D, Leonard BE. 1982. The effect of D-amphetamine and amitriptyline administered to pregnant rats on the locomotor activity and neurotransmitters of the offspring. Psychopharmacology 77:371-375.
24. Billing L, Eriksson M, Larsson G, Zetterström R. 1980. Amphetamine addiction and pregnancy. 3. One year follow-up of the children.-psychosocial and pediatric aspects. Acta Paediatr Scand 69:675-680.
25. Billing L, Eriksson M, Steneroth G, Zetterström R. 1985. Pre-school children of amphetamine-addicted mothers. I. Somatic and psychomotor development. Acta Paediatr Scand 74:179-184.
26. Billing L, Eriksson M, Steneroth G, Zetterström R. 1988. Predictive indicators for adjustment in 4-year-old children whose mothers used amphetamine during pregnancy. Child Abuse Negl 12:503-507.
27. Blaesing B, Nossoll M, Teuchert-Noodt G, Dawirs RR. 2001. Postnatal maturation of prefrontal pyramidal neurones is sensitive to a single early dose of methamphetamine in gerbils (Meriones unguiculatus). J Neural Transm 108:101-113.
28. Boe NM, Eby-Wilkens E, Field NT, Hedriana HL, Gilbert WM. 1999. Methamphetamine use during pregnancy increases the risk of adverse maternal and neonatal outcomes. Am J Obstet Gynecol 180:571.
29. Borcherding BG, Keysor CS, Rapoport JL, Elia J, Amass J. 1990. Motor/vocal tics and compulsive behaviors on stimulant drugs: is there a common vulnerability? Psychiatry Res 33:83-94.
30. Bost RO, Kemp P, Hnilica V. 1989. Tissue distribution of methamphetamine and amphetamine in premature infants. J Anal Toxicol 13:300-302.
31. Briggs GG, Samson JH, Crawford DJ. 1975. Lack of abnormalities in a newborn exposed to amphetamine during gestation. Am J Dis Child 129:249-250.
32. Brown GL, Ebert MH, Mikkelsen EJ, Hunt RD. 1980. Behavior and motor activity response in hyperactive children and plasma amphetamine levels following a sustained release preparation. J Am Acad Child Psychiatry 19:225-239.
33. Brown GL, Hunt RD, Ebert MH, Bunney WE Jr, Kopin IJ. 1979. Plasma levels of d-amphetamine in hyperactive children. Serial behavior and motor responses. Psychopharmacology (Berl) 62:133-140.
34. Buelke-Sam J, Kimmel CA, Adams J, Nelson CJ, Vorhees CV, Wright DC, St Omer V, Korol BA, Butcher RE, Geyer MA, et al. 1985. Collaborative Behavioral Teratology Study: results. Neurobehav Toxicol Teratol 7:591-624.
35. Burchfield DJ, Lucas VW, Abrams RM, Miller RL, DeVane CL. 1991. Disposition and pharmacodynamics of methamphetamine in pregnant sheep. JAMA 265:1968-1973.
36. Cabrera TM, Levy AD, Li Q, van de Kar LD, Battaglia G. 1993. Prenatal methamphetamine attenuates serotonin mediated renin secretion in male and female rat progeny: evidence for selective long-term dysfunction of serotonin pathways in brain. Synapse 15:198-208.
37. Caldwell J, Dring LG, Williams RT. 1972. Metabolism of (14 C)methamphetamine in man, the guinea pig and the rat. Biochem J 129:11-22.
38. Call TD, Hartneck J, Dickinson WA, Hartman CW, Bartel AG. 1982. Acute cardiomyopathy secondary to intravenous amphetamine abuse. Ann Intern Med 97:559-560.
39. Cameron RH, Kolesari GL, Kalbfleisch JH. 1983. Pharmacology of dextroamphetamine-induced cardiovascular malformations in the chick embryo. Teratology 27:253-259.
40. Cameron RH, Kolesari GL, Rajala GM. 1984. Elevated blood pressure in the embryonic chick induced by a teratogenic dose of dextroamphetamine sulfate. Teratology 29:87-92.
41. Cappon GD, Vorhees CV. 2001. Plasma and brain methamphetamine concentrations in neonatal rats. Neurotoxicol Teratol 23:81-88.
42. Castellanos FX, Giedd JN, Elia J, Marsh WL, Ritchie GF, Hamburger SD, Rapoport JL. 1997. Controlled stimulant treatment of ADHD and comorbid Tourette's syndrome: effects of stimulant and dose. J Am Acad Child Adolesc Psychiatry 36:589-596.
43. Cates NR. 1970. Effects of psychoactive drugs on sperm motility. Res Commun Chem Pathol Pharmacol 1:223-229.
44. Cernerud L, Eriksson M, Jonsson B, Steneroth G, Zetterström R. 1996. Amphetamine addiction during pregnancy: 14-year follow-up of growth and school performance. Acta Paediatr 85:204-208.
45. ChemIDplus. 2004a. Amphetamine. Available at http://chem2.sis.nlm. nih.gov/chemidplus/ProxyServlet?objectHandle = DBMaint&action Handle = default&nextPage = jsp/chemidlite/ResultScreen.jsp& TXTSUPERLISTID = 000300629. National Library of Medicine.
46. ChemIDplus. 2004b. Methylphenidate. Available at http://chem2. sis.nlm.nih.gov/chemidplus/ProxyServlet?objectHandle = DBMaint &actionHandle = default&nextPage = jsp/chemidlite/ResultScreen. jsp&TXTSUPERLISTID = 000113451. National Library of Medicine.
47. Chilcoat HD, Breslau N. 1999. Pathways from ADHD to early drug use. J Am Acad Child Adolesc Psychiatry 38:1347-1354.
48. Ching M, Tang L. 1986. Neuroleptic drug-induced alterations on neonatal growth and development. I. Prenatal exposure influences birth size, mortality rate, and the neuroendocrine system. Biol Neonate 49:261-269.
49. Cho AK, Melega WP, Kuczenski R, Segal DS. 2001. Relevance of pharmacokinetic parameters in animal models of methamphetamine abuse. Synapse 39:161-166.
50. Cho DH, Lyu HM, Lee HB, Kim PY, Chin K. 1991. Behavioral teratogenicity of methamphetamine. J Toxicol Sci 16(Suppl):37-49.
51. Clark CH, Gorman D, Vernadakis A. 1970. Effects of prenatal administration of psychotropic drugs on behavior of developing rats. Dev Psychobiol 3:225-235.
52. Cook CE, Jeffcoat AR, Hill JM, Pugh DE, Patetta PK, Sadler BM, White WR, Perez-Reyes M. 1993. Pharmacokinetics of methamphetaanine self-administered to human subjects by smoking S-(+)-methamphetamine hydrochloride. Drug Metab Dispos 21:717-723.
53. Cook CE, Jeffcoat AR, Sadler BM, Hill JM, Voyksner RD, Pugh DE, White WR, Perez-Reyes M. 1992. Pharmacokinetics of oral methamphetamine and effects of repeated daily dosing in humans. Drug Metab Dispos 20:856-862.
54. Courtney KD, Valerio DA. 1968. Teratology in the Macaca mulatta. Teratology 1:163-172.
55. Crawford CA, Williams MT, Newman ER, McDougall SA, Vorhees CV. 2003. Methamphetamine exposure during the preweanling period causes prolonged changes in dorsal striatal protein kinase A activity, dopamine D2-like binding sites, and dopamine content. Synapse 48:131-137.
56. Crawford CA, Zavala AR, Karper PE, Collins RL, Loring-Meier T, Watson JB, McDougall SA. 2000a. Amphetamine treatment during the preweanling period produces enduring changes in striatal protein kinase A activity. Pharmacol Biochem Behav 66:835-840.
57. Crawford CA, Zavala AR, Karper PE, McDougall SA. 2000b. Long-term effects of postnatal amphetamine treatment on striatal protein kinase A activity, dopamine D(1)-like and D(2)-like binding sites, and dopamine content. Neurotoxicol Teratol 22:799-804.
58. DeVane CL. 1994. Pharmacogenetics and drug metabolism of newer antidepressant agents. J Clin Psychiatry 55(Suppl):38-47.
59. Dickinson J, Andres R, Parisi V 1994. The ovine fetal sympathoadrenal response to the maternal administration of methamphetamine. Am J Obstet Gynecol 170:1452-1457.
60. Dixon SD, Bejar R. 1989. Echoencephalographic findings in neonates associated with maternal cocaine and methamphetamine use: incidence and clinical correlates. J Pediatr 115:770-778.
61. Dominguez R, Vila-Coro AA, Slopis JM, Bohan TP. 1991. Brain and ocular abnormalities in infants with in utero exposure to cocaine and other street drugs. Am J Dis Child 145:688-695.
62. Dring LG, Smith RL, Williams RT. 1970. The metabolic fate of amphetamine in man and other species. Biochem J 116:425-435.
63. DEA. 2004. DEA web site. Available at: http://www.usdoj.gov/dea/index. htm.
64. Duke MA, O'Neal J, McDougall SA. 1997. Ontogeny of dopamine agonist-induced sensitization: role of NMDA receptors. Psychopharmacology (Berl) 129:153-160.
65. Dunnick JK, Eustis SL. 1991. Decreases in spontaneous tumors in rats and mice after treatment with amphetamine. Toxicology 67:325-332.
66. Efron D, Jarman F, Barker M. 1997. Side effects of methylphenidate and dexamphetamine in children with attention deficit hyperactivity disorder: a double-blind, crossover trial. Pediatrics 100:662-666.
67. Ehrlich ME, Sommer J, Canas E, Unterwald EM. 2002. Periadolescent mice show enhanced ΔFosB upregulation in response to cocaine and amphetamine. J Neurosci 22:9155-9159.
68. Erenberg G, Cruse RP, Rothner AD. 1985. Gilles de la Tourette's syndrome: effects of stimulant drugs. Neurology 35:1346-1348.
69. Eriksson M, Billing L, Steneroth G, Zetterström R. 1985. Pre-school children of amphetamine-addicted mothers. II. Environment and supportive social welfare. Acta Paediatr Scand 74:185-190.
70. Eriksson M, Billing L, Steneroth G, Zetterström R. 1989. Health and development of 8-year-old children whose mothers abused amphetamine during pregnancy. Acta Paediatr Scand 78:944-949.
71. Eriksson M, Cernerud L, Johnson B, Steneroth G, Zetterstrom R. 1994. Amphetamine abuse during pregnancy: longterm follow-up of exposed children. Teratology 50:45A.
72. Eriksson M, Jonsson B, Steneroth G, Zetterström R. 2000. Amphetamine abuse during pregnancy: environmental factors and outcome after 14-15 years. Scand J Public Health 28:154-157.
73. Eriksson M, Larsson G, Winbladh B, Zetterstrom R. 1978. The influence of amphetamine addiction on pregnancy and the newborn infant. Acta Paediatr Scand 67:95-99.
74. Eriksson M, Larsson G, Zetterström R. 1981. Amphetamine addiction and pregnancy. II. Pregnancy, delivery and the neonatal period. Sociomedical aspects. Acta Obstet Gynecol Scand 60:253-259.
75. Eriksson M, Zetterström R. 1994. Amphetamine addiction during pregnancy: 10-year follow-up. Acta Paediatr Suppl 404:27-31.
76. FDA. 2001. Adderal XR: Chemistry Review(s), Clinical Pharmacology and Biopharmaceutics Reviews(s), Medical Review, Pharmacology Review, and Statistical Review. Center for Drug Evaluation and Research. Report nr 21-303.
77. FDA. 2002. Adderal: Chemistry Review(s), Clinical Pharmacology and Biopharmaceutics Reviews(s), and Medical Review. Center for Drug Evaluation and Research. Report nr 11-522/S-030.
78. FDA. 2004. Drugs at FDA. Available at: http://www.accessdata.fda.gov/ scripts/cder/drugsatfda/index.cfm. FDA CDER.
79. Fein A, Shviro Y, Manoach M, Nebel L. 1987. Teratogenic effect of D-amphetamine sulfate: histodifferentiation and electrocardiogram pattern of mouse embryonic heart. Teratology 35:27-34.
80. Felix RJ, Chambers CD, Dick LM, Johnson KA, Jones KL. 2000. Prospective pregnancy outcome in women exposed to amphetamines. Teratology 61:441.
81. Finnegan LP, Ehrlich SM. 1990. Maternal drug abuse during pregnancy: evaluation and pharmacotherapy for neonatal abstinence. Mod Methods Pharmacol 6:255-263.
82. Fischer M, Barkley RA. 2003. Childhood stimulant treatment and risk for later substance abuse. J Clin Psychiatry 64(Suppl):19-23.
83. Fujiwara Y, Kazahaya Y, Nakashima M, Sato M, Otsuki S. 1987. Behavioral sensitization to methamphetamine in the rat: an ontogenic study. Psychopharmacology (Berl) 91:316-319.
84. Fukui R, Svenningsson P, Matsuishi T, Higashi H, Nairn AC, Greengard P, Nishi A. 2003. Effect of methylphenidate on dopamine/DARPP signalling in adult, but not young, mice. J Neurochem 87:1391-1401.
85. Fukumura M, Cappon GD, Broening HW, Vorhees CV. 1998. Methamphetamine-induced dopamine and serotonin reductions in neostriatum are not gender specific in rats with comparable hyperthermic responses. Neurotoxicol Teratol 20:441-448.
86. Furara SA, Carriek P, Armstrong D, Pairaudeau P, Pullan AM, Lindow SW. 1999. The outcome of pregnancy associated with amphetamine use. J Obstet Gynaecol 19:377-380.
87. Furst SR, Fallon SP, Reznik GN, Shah PK. 1990. Myocardial infarction after inhalation of methamphetamine. N Engl J Med 323:1147-1148.
88. Gao X, Dluzen DE. 2001. The effect of testosterone upon methamphetamine neurotoxicity of the nigrostriatal dopaminergic system. Brain Res 892:63-69.
89. Garriott JC, Spruill FG. 1973. Detection of methamphetamine in a newborn infant. J Forensic Sci 18:434-436.
90. Gazzara RA, Fisher RS, Howard SG. 1986. The ontogeny of amphetamine-induced dopamine release in the caudate-putamen of the rat. Brain Res 393:213-220.
91. Gillogley KM, Evans AT, Hansen RL, Samuels SJ, Batra KK. 1990. The perinatal impact of cocaine, amphetamine, and opiate use detected by universal intrapartum screening. Am J Obstet Gynecol 163:1535-1542.
92. Ginsberg MD, Hertzman M, Schmidt-Nowara WW. 1970. Amphetamine intoxication with coagulopathy, hyperthermia, and reversible renal failure. A syndrome resembling heatstroke. Ann Intern Med 73:81-85.
93. Golden GS. 1974. Gilles de la Tourette's syndrome following methylphenidate administration. Dev Med Child Neurol 16:76-78.
94. Golden GS. 1977. The effect of central nervous system stimulants on Tourette syndrome. Ann Neurol 2:69-70.
95. Gomes-da-Silva J, Perez-Rosado A, de Miguel R, Fernandez-Ruiz J, Silva MC, Tavares MA. 2002. Prenatal exposure to methamphetamine in the rat: ontogeny of tyrosine hydroxylase mRNA expression in mesencephalic dopaminergic neurons. Ann NY Acad Sci 965:68-77.
96. Gospe SM Jr. 1995. Transient cortical blindness in an infant exposed to methamphetamine. Ann Emerg Med 26:380-382.
97. Greaves C. 1972. Sexual disturbances among chronic amphetamine users. J Nerv Ment Dis 155:363-365.
98. Greenberg LM, Deem MA, McMahon S. 1972. Effects of dextroamphetamine, chlorpromazine, and hydroxyzine on behavior and performance in hyperactive children. Am J Psychiatry 129:532-539.
99. Greenhill LL. 1992. Pharmacologic treatment of attention deficit hyperactivity disorder. Psychiatr Clin North Am 15:1-27.
100. Greenhill LL, Puig-Antich J, Chambers W, Rubinstein B, Halpern F, Sachar EJ. 1981. Growth hormone, prolactin, and growth responses in hyperkinetic males treated with d-amphetamine. J Am Acad Child Psychiatry 20:84-103.
101. Greenhill LL, Puig-Antich J, Sassin J, Sachar EJ. 1977. Hormone and growth responses in hyperkinetic children on stimulant medication [proceedings]. Psychopharmacol Bull 13:33-36.
102. Greenhill LL, Swanson JM, Steinhoff K, Fried J, Posner K, Lerner M, Wigal S, Clausen SB, Zhang Y, Tulloch S. 2003. A pharmacokinetic/pharmacodynamic study comparing a single morning dose of adderall to twice-daily dosing in children with ADHD. J Am Acad Child Adolesc Psychiatry 42:1234-1241.
103. Gross MD. 1976. Growth of hyperkinetic children taking methylphenidate, dextroamphetamine, or imipramine/desipramine. Pediatrics 58:423-431.
104. Hall RC, Popkin MK, Beresford TP, Hall AK. 1988. Amphetamine psychosis: clinical presentations and differential diagnosis. Psychiatr Med 6:73-79.
105. Hansen RL, Struthers JM, Gospe SM Jr. 1993. Visual evoked potentials and visual processing in stimulant drug-exposed infants. Dev Med Child Neurol 35:798-805.
106. Harris DS, Boxenbaum H, Everhart ET, Sequeira G, Mendelson JE, Jones RT. 2003. The bioavailability of intranasal and smoked methamphetamine. Clin Pharmacol Ther 74:475-486.
107. Heinonen OP. 1977. Birth defects and drugs in pregnancy. Littleton, MA: Publishing Sciences Group Inc.
108. Heller A, Bubula N, Freeney A, Won L. 2001a. Elevation of fetal dopamine following exposure to methamphetamine in utero. Brain Res Dev Brain Res 130:139-142.
109. Heller A, Bubula N, Lew R, Heller B, Won L. 2001b. Gender-dependent enhanced adult neurotoxic response to methamphetamine following fetal exposure to the drug. J Pharmacol Exp Ther 298:769-779.
110. Hemmer SA, Pasternak JF, Zecker SG, Trommer BL. 2001. Stimulant therapy and seizure risk in children with ADHD. Pediatr Neurol 24:99-102.
111. Hines RN, McCarver DG. 2002. The ontogeny of human drug-metabolizing enzymes: phase 1 oxidative enzymes. J Pharmacol Exp Ther 300:355-360.
112. Hitzemann BA, Hitzemann RJ, Brase DA, Loh HH. 1976. Influence of prenatal D-amphetamine administration on development and behavior of rats. Life Sci 18:605-612.
113. Holson R, Adams J, Buelke-Sam J, Gough B, Kimmel CA. 1985. d-Amphetamine as a behavioral teratogen: effects depend on dose, sex, age and task. Neurobehav Toxicol Teratol 7:753-758.
114. Hong R, Matsuyama E, Nur K. 1991. Cardiomyopathy associated with the smoking of crystal methamphetamine. Jama 265:1152-1154.
115. HSDB. 2002. Methylphenidate. Available at http://toxnet.nlm.nih.gov/cgi- bin/sis/search/f?./temp/~PMHalx:1. National Library of Medicine.
116. HSDB. 2004. Amphetamine. Available at: http://toxnet.nlm.nih.gov/cgi-bin/ sis/htmlgen?HSDB.
117. Joffe GM, Kasnic T. 1994. Medical prescription of dextroamphetamine during pregnancy. J Perinatol 14:301-303.
118. Jones SR, Gainetdinov RR, Wightman RM, Caron MG. 1998. Mechanisms of amphetamine action revealed in mice lacking the dopamine transporter. J Neurosci 18:1979-1986.
119. Kase CS. 1986. Intracerebral hemorrhage: non-hypertensive causes. Stroke 17:590-595.
120. Kasirsky G, Tansy MF. 1971. Teratogenic effects of methamphetamine in mice and rabbits. Teratology 4:131-134.
121. Kendrick WC, Hull AR, Knochel JP. 1977. Rhabdomyolysis and shock after intravenous amphetamine administration. Ann Intern Med 86:381-387.
122. Kimmel CA, Buelke-Sam J. 1985. Collaborative Behavioral Teratology Study: background and overview. Neurobehav Toxicol Teratol 7:541-545.
123. Kimmel CA, Buelke-Sam J, Adams J. 1985. Collaborative Behavioral Teratology Study: implications, current applications and future directions. Neurobehav Toxicol Teratol 7:669-673.
124. Kita T, Wagner GC, Nakashima T. 2003. Current research on methamphetamine-induced neurotoxicity: animal models of monoamine disruption. J Pharmacol Sci 92:178-195.
125. Kolesari GL, Kaplan S. 1979. Amphetamines reduce embryonic size and produce caudal hematomas during early chick morphogenesis. Teratology 20:403-412.
126. Kolta MG, Scalzo FM, Ali SF, Holson RR. 1990. Ontogeny of the enhanced behavioral response to amphetamine in amphetamine-pretreated rats. Psychopharmacology (Berl) 100:377-382.
127. Kontur PJ, Won LA, Hoffmann PC, Heller A. 1991. Survival of developing dopaminergic neurons in reaggregate tissue culture following treatment with methamphetamine. Neurosci Lett 129:254-258.
128. Kraemer T, Maurer HH. 2002. Toxicokinetics of amphetamines: metabolism and toxicokinetic data of designer drugs, amphetamine, methamphetamine, and their N-alkyl derivatives. Ther Drug Monit 24:277-289.
129. Lal S, Sourkes TL. 1973. Ontogeny of stereotyped behaviour induced by apomorphine and amphetamine in the rat. Arch Int Pharmacodyn Ther 202:171-182.
130. Lambert NM. 2002. Stimulant treatment as a risk factor for nicotine use and substance abuse. In: Jensen PS, Cooper JR, editors. Attention deficit hyperactivity disorder. Kingston, NJ: Civic Research Institute.
131. Lambert NM, Hartsough CS. 1998. Prospective study of tobacco smoking and substance dependencies among samples of ADHD and non-ADHD participants. J Learn Disabil 31:533-544.
132. Lanier LP, Isaacson RL. 1977. Early developmental changes in the locomotor response to amphetamine and their relation to hippocampal function. Brain Res 126:567-575.
133. Larez A, Briceno E, Ochoa Y, Montenegro M, Aponte N. 1979. Mutagenicity obtained experimentally by oral administration of dextroamphetamine sulphate to the rat. Bull Narc 31:67-70.
134. Larsson G. 1980. The amphetamine addicted mother and her child. Acta Paediatr Scand Suppl 278:1-24.
135. Larsson G, Eriksson M, Zetterström R. 1979. Amphetamine addiction and pregnancy. Psycho-social and medical aspects. Acta Psychiatr Scand 60:334-346.
136. Laviola G, Adriani W, Morley-Fletcher S, Terranova ML. 2002. Peculiar response of adolescent mice to acute and chronic stress and to amphetamine: evidence of sex differences. Behav Brain Res 130:117-125.
137. Leckman JF. 2003. Phenomenology of tics and natural history of tic disorders. Brain Dev 25(Suppl):S24-S28.
138. Levin JN. 1971. Amphetamine ingestion with biliary atresia. J Pediatr 79:130-131.
139. Lipkin PH, Goldstein IJ, Adesman AR. 1994. Tics and dyskinesias associated with stimulant treatment in attention-deficit hyperactivity disorder. Arch Pediatr Adolesc Med 148:859-861.
140. Little BB, Snell LM, Gilstrap LC 3rd, 1988. Methamphetamine abuse during pregnancy: outcome and fetal effects. Obstet Gynecol 72:541-544.
141. Loney J, Kramer JR, Salisbury H. 2002. Medicated versus unmedicated ADHD children: adult involvement with legal and illegal drugs. In: Jensen PS, Cooper JR, editors. Attention deficit hyperactivity disorder. Kingston, NJ: Civic Research Institute, p 1-16.
142. Lowe TL, Cohen DJ, Detlor J, Kremenitzer MW, Shaywitz BA. 1982. Stimulant medications precipitate Tourette's syndrome. JAMA 247:1729-1731.
143. Lucot JB, Wagner GC, Schuster CR, Seiden LS. 1982. Decreased sensitivity of rat pups to long-lasting dopamine and serotonin depletions produced by methylamphetamine. Brain Res 247:181-183.
144. Madras BK, Miller GM, Fischman AJ. 2002. The dopamine transporter: relevance to attention deficit hyperactivity disorder (ADHD). Behav Brain Res 130:57-63.
145. Markowitz JS, Morrison SD, DeVane CL. 1999. Drug interactions with psychostimulants. Int Clin Psychopharmacol 14:1-18.
146. Markowitz JS, Patrick KS. 2001. Pharmacokinetic and pharmacodynamic drug interactions in the treatment of attention-deficit hyperactivity disorder. Clin Pharmacokinet 40:753-772.
147. Martin JC. 1975. Effects on offspring of chronic maternal methamphetamine exposure. Dev Psychobiol 8:397-404.
148. Martin JC, Martin DC. 1981. Voluntary activity in the aging rat as a function of maternal drug exposure. Neurobehav Toxicol Teratol 3:261-264.
149. Martin JC, Martin DC, Radow B, Sigman G. 1976. Growth, development and activity in rat offspring following maternal drug exposure. Exp Aging Res 2:235-251.
150. Martin JC, Martin DC, Sigman G, Day-Pfeiffer H. 1983. Saccharin preferences in food deprived aging rats are altered as a function of perinatal drug exposure. Physiol Behav 30:853-858.
151. Martin JC, Martin DD, Radow B, Day HE. 1979. Life span and pathology in offspring following nicotine and methamphetamine exposure. Exp Aging Res 5:509-522.
152. McCann UD, Ricaurte GA. 2004. Amphetamine neurotoxicity: accomplishments and remaining challenges. Neurosci Biobehav Rev 27:821-826.
153. McDougall SA, Duke MA, Bolanos CA, Crawford CA. 1994. Ontogeny of behavioral sensitization in the rat: effects of direct and indirect dopamine agonists. Psychopharmacology (Berl) 116:483-490.
154. McElhatton PR, Bateman DN, Evans C, Pughe KR, Thomas SH. 1999. Congenital anomalies after prenatal ecstasy exposure. Lancet 354:1441-1442.
155. McElhatton PR, Pughe KR, Evans C, Porter K, Bateman DN, Thomas SH. 2000. Is exposure to amphetamine-like drugs in pregnancy associated with malformations? J Toxicol Clin Toxicol 38:195-196.
156. Michael MI, Khalil SH, Matta CA, Rizk TA. 1987. Normal development of the prenatal mouse eye. Folia Morphol (Praha) 35:228-236.
157. Middaugh LD, Blackwell LA, Santos CA 3rd, Zemp JW. 1974. Effects of d-amphetamine sulfate given to pregnant mice on activity and on catecholamines in the brains of offspring. Dev Psychobiol 7:429-438.
158. Milkovich L, van den Berg BJ. 1977. Effects of antenatal exposure to anorectic drugs. Am J Obstet Gynecol 129:637-642.
159. Monder H. 1981. Effects of prenatal amphetamine exposure on the development of behavior in rats. Psychopharmacology (Berl) 75:75-78.
160. Musshoff F. 2000. Illegal or legitimate use? Precursor compounds to amphetamine and methamphetamine. Drug Metab Rev 32:15-44.
161. Naeye RL. 1983. Maternal use of dextroamphetamine and growth of the fetus. Pharmacology 26:117-120.
162. Nasello AG, Astrada CA, Ramirez OA. 1974. Effects on the acquisition of conditioned avoidance responses and seizure threshold in the offspring of amphetamine treated gravid rats. Psychopharmacologia 40:25-31.
163. Nasello AG, Ramirez OA. 1978. Open-field and Lashley III maze behaviour of the offspring of amphetamine-treated rats. Psychopharmacology (Berl) 58:171-173.
164. Nelson CJ, Felton RP, Kimmel CA, Buelke-Sam J, Adams J. 1985. Collaborative Behavioral Teratology Study: statistical approach. Neurobehav Toxicol Teratol 7:587-590.
165. Nelson MM, Forfar JO. 1971. Associations between drugs administered during pregnancy and congenital abnormalities of the fetus. Br Med J 1:523-527.
166. NIDA. 2003. InfoFacts: methamphetamine. Available at http://165.112.78. 61/Infofax/methamphetamine.html. National Institute on Drug Abuse.
167. NlOSH. 2001. RTECS report for phenethylamine, N.alpha-dimethyl-, hydrochloride, (S) - (+). Available at http://www.cdc.gov/niosh/rtecs/sh533c98. html. NIOSH.
168. NIOSH. 2002. RTECS report for phenethylamine, alpha-methyl-, sulfate (2:1), (+-)-. Available at http://www.cdc.gov/niosh/rtecs/silab3f0.html. NIOSH.
169. Nora JJ, McNamara DG, Fraser FC. 1967. Dexamphetamine Sulfate and Human Malformations. Lancet 1:570-571.
170. Nora JJ, Sommerville RJ, Fraser FC. 1968. Homologies for congenital heart diseases: murine models, influenced by dextroamphetamine. Teratology 1:413-416.
171. Nora JJ, Trasler DG, Fraser FC. 1965. Malformations in mice induced by dexamphetamine sulphate. Lancet 2:1021-1022.
172. Nora JJ, Vargo TA, Nora AH, Love KE, McNamara DG. 1970. Dexamphetamine: a possible environmental trigger in cardiovascular malformations. Lancet 1:1290-1291.
173. NTP. 1991. Toxicology and carcinogenesis studies of dl-amphetamine sulfate (CAS No. 60-13-9) in F344/N rats and B6C3F1 mice (feed studies). Research Triangle Park, NC: NTP, U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health. Report nr NTP-TR-387.
174. O'Connor JC, Davis LG, Frame SR, Cook JC. 2000. Evaluation of a Tier I screening battery for detecting endocrine-active compounds (EACs) using the positive controls testosterone, eoumestrol, progesterone, and RU486. Toxicol Sci 54:338-354.
175. Oregon Department of Human Services. 2003. Children in methamphetamine "labs" in Oregon. CD Summary 52(16).
176. Oro AS, Dixon SD. 1987. Perinatal cocaine and methamphetamine exposure: maternal and neonatal correlates. J Pediatr 111:571-578.
177. Palmowski AM, Tulsi RS. 1987. A quantitative and qualitative study of craniofacial development in the rat embryo aged 302 hr to 374 hr (days 12.5 to 15.5). J Craniofac Genet Dev Biol 7:331-340.
178. Paternite CE, Loney J, Salisbury H, Whaley MA. 1999. Childhood inattention-overactivity, aggression, and stimulant medication history as predictors of young adult outcomes. J Child Adolesc Psychopharmacol 9:169-184.
179. PDR. 2003a. Adderall Tablets (Shire U.S.). Thompson Medical Economics.
180. PDR. 2003b. Adderall XR™ Capsules (Shire U.S.). Thompson Medical Economics.
181. PDR. 2003c. Desoxyn Tablets (Abbott). Thompson Medical Economics.
182. PDR. 2003d. Dexedrine spansule capsules, Dexedrine tablets (GlaxoSmithKline). Thompson Medical Ecomonomics.
183. PDR. 2003e. DextroStat Tablets (Shire U.S.). Thompson Medical Economics.
184. Perez JA Jr, Arsura EL, Strategos S. 1999. Methamphetamine-related stroke: four cases. J Emerg Med 17:469-471.
185. Poulton A, Cowell CT. 2003. Slowing of growth in height and weight on stimulants: a characteristic pattern. J Paediatr Child Health 39:180-185.
186. Price RA, Leckman JF, Pauls DL, Cohen DJ, Kidd KK. 1986. Gilles de la Tourette's syndrome: tics and central nervous system stimulants in twins and nontwins. Neurology 36:232-237.
187. Pu C, Broening HW, Vorhees CV. 1996. Effect of methamphetamine on glutamate-positive neurons in the adult and developing rat somatosensory cortex. Synapse 23:328-334.
188. Pu C, Vorhees CV. 1993. Developmental dissociation of methamphetamine-induced depletion of dopaminergic terminals and astrocyte reaction in rat striatum. Brain Res Dev Brain Res 72:325-328.
189. Puig-Antich J, Greenhill LL, Sassin J, Sachar EJ. 1978. Growth hormone, prolactin and cortisol responses and growth patterns in hyperkinetic children treated with dextro-amphetamine. Preliminary findings. J Am Acad Child Psychiatry 17:457-475.
190. Ramirez OA, Carrer HF. 1983. Noradrenergic modulation of neuronal transmission in the offspring of amphetamine-treated rats. Can J Physiol Pharmacol 61:766-769.
191. Ramirez OA, Carrer HF, Nasello AG. 1979, Prenatal amphetamine exposure: ovulation, sexual behavior and hypothalamic monoamine content in rats. Pharmacol Biochem Behav 11:605-609.
192. Ramirez OA, Keller EA, Orsingher OA. 1983. Prenatal amphetamine reduces alpha but not beta adrenergic receptor binding in brain of adult rats. Life Sci 32:1835-1838.
193. Rapoport JL, Buchsbaum MS, Weingartner H, Zahn TP, Ludlow C, Mikkelsen EJ. 1980. Dextroamphetamine. Its cognitive and behavioral effects in normal and hyperactive boys and normal men. Arch Gen Psychiatry 37:933-943.
194. Rhodium. 2004. Rhodium web site. Available at: http://www.rhodium.ws/ chemistry/index.html.
195. Rothrock JF, Rubenstein R, Lyden PD. 1988. Ischemic stroke associated with methamphetamine inhalation. Neurology 38:589-592.
196. Safer D, Allen R, Barr E. 1972. Depression of growth in hyperactive children on stimulant drugs. N Engl J Med 287:217-220.
197. Safer DJ, Allen RP. 1973. Factors influencing the suppressant effects of
198. Safer DJ, Allen RP, Barr E. 1975. Growth rebound after termination of stimulant drugs. J Pediatr 86:113-116.
199. Saito TR, Aoki S, Saito M, Amao H, Niwa T, Terada M, Sugiyama M, Takahashi KW. 1991. Effects of methamphetamine on copulatory behavior in male rats. Jikken Dobutsu 40:447-452.
200. Satinder KP, Sterling JW. 1983. Differential effects of pre- and/or postnatal d-amphetamine on avoidance response in genetically selected lines of rats. Neurobehav Toxicol Teratol 5:315-320.
201. Sato M, Fujiwara Y. 1986. Behavioral and neurochemical changes in pups prenatally exposed to methamphetamine. Brain Dev 8:390-396.
202. Schaiberger PH, Kennedy TC, Miller FC, Gal J, Petty TL. 1993. Pulmonary hypertension associated with long-term inhalation of "crank" methamphetamine. Chest 104:614-616.
203. Schertz M, Adesman AR, Alfieri NE, Bienkowski RS. 1996. Predictors of weight loss in children with attention deficit hyperactivity disorder treated with stimulant medication. Pediatrics 98:763-769.
204. Schnieden H. 1974. The effect of some psychoactive drugs and metallic salts on the motility of rabbit spermatozoa. ICRS J Int Res Commun 2:1507.
205. Seeker R. 2004. Comments on the draft NTP-CERHR Expert Panel report on the reproductive and developmental toxicity of amphetamine and methamphetamine. Hampshire, UK: Shire Pharmaceuticals Group.
206. Seliger DL. 1973. Effect of prenatal maternal administration of D-amphetamine on rat offspring activity and passive avoidance learning. Physiol Psychol 1:273-280.
207. Seliger DL. 1975. Prenatal maternal d-amphetamine effects on emotionality and audiogenic seizure susceptibility of rat offspring. Dev Psychobiol 8:261-268.
208. Sellers EM, Otton SV, Tyndale RF. 1997. The potential role of the cytochrome P-450 2D6 pharmcogenetic polymorphism in drug abuse. NIDA Research Monograph Series 173:6-26.
209. Sherman MP, Wheeler-Sherman J. 2000. Cranky babies: outcomes associated with prenatal amphetamine exposure. J Perinatol 20:478.
210. Smith L, Yonekura ML, Wallace T, Berman N, Kuo J, Berkowitz C. 2003. Effects of prenatal methamphetamine exposure on fetal growth and drug withdrawal symptoms in infants born at term. J Dev Behav Pediatr 24:17-23.
211. Smith LM, Chang L, Yonekura ML, Grob C, Osborn D, Ernst T. 2001. Brain proton magnetic resonance spectroscopy in children exposed to methamphetamine in utero. Neurology 57:255-260.
212. Solanto MV. 2000. Clinical psychopharmacology of AD/HD: implications for animal models. Neurosci Biobehav Rev 24:27-30.
213. Spencer TJ, Biederman J, Harding M, O'Donnell D, Faraone SV, Wilens TE. 1996. Growth deficits in ADHD children revisited: evidence for disorder-associated growth delays? J Am Acad Child Adolesc Psychiatry 35:1460-1469.
214. Steiner E, Villen T, Hallberg M, Rane A. 1984. Amphetamine secretion in breast milk. Eur J Clin Pharmacol 27:123-124.
215. Stek AM, Baker RS, Fisher BK, Lang U, Clark KE. 1995. Fetal responses to maternal and fetal methamphetamine administration in sheep. Am J Obstet Gynecol 173:1592-1598.
216. Stek AM, Fisher BK, Baker RS, Lang U, Tseng CY, Clark KE. 1993. Maternal and fetal cardiovascular responses to methamphetamine in the pregnant sheep. Am J Obstet Gynecol 169:888-897.
217. Stewart JL, Meeker JE. 1997. Fetal and infant deaths associated with maternal methamphetamine abuse. J Anal Toxicol 21:515-517.
218. Sund AM, Zeiner P. 2002. Does extended medication with amphetamine or methylphenidate reduce growth in hyperactive children? Nord J Psychiatry 56:53-57.
219. Tan SE. 2003. Prenatal amphetamine exposure alters behavioral reactivity to amphetamine in rats. Neurotoxicol Teratol 25:579-585.
220. Tariq M, Parmar NS, Qureshi S, el-Feraly FS, Al-Meshal IA. 1987. Clastogenic evaluation of cathinone and amphetamine in somatic cells of mice. Mutat Res 190:153-157.
221. Tavares MA, Silva MC. 1993. Body weight gain and hippocampal volumes of rats exposed neonatally to psychostimulants. Brain Res 619:137-145.
222. Tavares MA, Silva MC, Silva-Araujo A, Xavier MR, Ali SF. 1996. Effects of prenatal exposure to amphetamine in the medial prefrontal cortex of the rat. Int J Dev Neurosci 14:585-596.
223. Tonge SR. 1973. Permanent alterations in catecholamine concentrations in discrete areas of brain in the offspring of rats treated with methylamphetamine and chlorpromazine. Br J Pharmacol 47:425-427.
224. Trent F, Nakamura S, Tepper JM. 1991. Amphetamine exerts anomalous effects on dopaminergic neurons in neonatal rats in vivo. Eur J Pharmacol 204:265-272.
225. Tsuchida K, Akiyama K, Sakai K, Ujike H, Li X, Kuroda S. 1996. Ontogeny of striatal dopamine release in rats after acute administration of methamphetamine. Pharmacol Biochem Behav 53:575-580.
226. Tsuchida K, Ujike H, Kanzaki A, Fujiwara Y, Akiyama K. 1994. Ontogeny of enhanced striatal dopamine release in rats with methamphetamine-induced behavioral sensitization. Pharmacology Biochemistry And Behavior 47:161-169.
227. U.S. Department of Justice. 2002. Children at risk. Information Bulletin: 1-7.
228. U.S. Department of Justice. 2003. Children at clandenstine methamphetamine labs: helping meth's youngest victims. OVC Bulletin:1-11.
229. UN. 2002. Psychotropic substances. Available at http://www.incb.org/e/ index.htm?: United Nations International Narcotics Control Board.
230. van Tonningen-van Driel MM, Garbis-Berkvens JM, Reuvers-Lodewijks WE. 1999. [Pregnancy outcome after ecstasy use; 43 cases followed by the Teratology Information Service of the National Institute for Public Health and Environment (RIVM)]. Ned Tijdschr Geneeskd 143:27-31.
231. Varley CK, Vincent J, Varley P, Calderon R. 2001. Emergence of tics in children with attention deficit hyperactivity disorder treated with stimulant medications. Compr Psychiatry 42:228-233.
232. Vorhees CV 1985. Behavioral effects of prenatal d-amphetamine in rats: a parallel trial to the Collaborative Behavioral Teratology Study. Neurobehav Toxicol Teratol 7:709-716.
233. Vorhees CV, Acuff-Smith KD. 1990. Prenatal methamphetamine-induced anophthalmia in rats. Neurotoxicol Teratol 12:409.
234. Vorhees CV, Ahrens KG, Acuff-Smith KD, Schilling MA, Fisher JE. 1994a. Methamphetamine exposure during early postnatal development in rats: I. Acoustic startle augmentation and spatial learning deficits. Psychopharmacology (Berl) 114:392-401.
235. Vorhees CV, Ahrens KG, Acuff-Smith KD, Schilling MA, Fisher JE. 1994b. Methamphetamine exposure during early postnatal development in rats: II. Hypoactivity and altered responses to pharmacological challenge. Psychopharmacology (Berl) 114:402-408.
236. Vorhees CV, Inman-Wood SL, Morford LL, Broening HW, Fukumura M, Moran MS. 2000. Adult learning deficits after neonatal exposure to D-methamphetamine: selective effects on spatial navigation and memory. J Neurosci 20:4732-4739.
237. Vorhees CV, Morford LL, Inman SL, Reed TM, Schilling MA, Cappon GD, Moran MS, Nebert DW. 1999. Genetic differences in spatial learning between Dark Agouti and Sprague-Dawley strains: possible correlation with the CYP2D2 polymorphism in rats treated neonatally with methamphetamine. Pharmacogenetics 9:171-181.
238. Vorhees CV, Pu C. 1995. Ontogeny of methamphetamine-induced neurotoxicity in the rat model. NIDA Res Monogr 158:149-171.
239. Vorhees CV, Reed TM, Schilling MA, Fisher JE, Moran MS, Cappon GD, Nebert DW. 1998. CYP2D1 polymorphism in methamphetamine-treated rats: genetic differences in neonatal mortality and effects on spatial learning and acoustic startle. Neurotoxicol Teratol 20:265-273.
240. Vorhees CV, Reed TM, Schilling MS, Acuff-Smith KD, Fisher JE, Moran MS. 1996. Neonatal methamphetamine-induced long-term acoustic startle facilitation in rats as a function of prepulse stimulus intensity. Neurotoxicol Teratol 18:135-139.
241. Wagner GC, Schuster CR, Seiden LS. 1981. Neurochemical consequences following administration of CNS stimulants to the neonatal rat. Pharmacol Biochem Behav 14:117-119.
242. Weissman AD, Caldecott-Hazard S. 1993. In utero methamphetamine effects: I. Behavior and monoamine uptake sites in adult offspring. Synapse 13:241-250.
243. White House Office of National Drug Control Policy. 2004. Statement of Scott Burns-Deputy Director for State and Local Affairs-White House Office of National Drug Control Policy-Before the House Committee on Government Reform-Subcommittee on Criminal Justice, Drug Policy and Human Resources-"Fighting Methamphetamine in the Heartland: How Can the Federal Government Assist State and Local Efforts?". Washington, DC: White House Office of National Drug Control Policy, p 1-10.
244. Wilens T. 2002. Attention deficit hyperactivity disorder and substance abuse disorders-the nature relationship, subtypes at risk, and treatment issues. In: Jensen PS, Cooper JR, editors. Attention deficit hyperactivity disorder. Kingston, NJ: Civic Research Institute, p 1-17.
245. Wilens TE, Faraone SV, Biederman J, Gunawardene S. 2003. Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature. Pediatrics 111:179-185.
246. Williams MT, Blankenmeyer TL, Schaefer TL, Brown CA, Gudelsky GA, Vorhees CV. 2003a. Long-term effects of neonatal methamphetamine exposure in rats on spatial learning in the Barnes maze and on cliff avoidance, corticosterone release, and neurotoxicity in adulthood. Brain Res Dev Brain Res 147:163-175.
247. Williams MT, Inman-Wood SL, Morford LL, McCrea AE, Ruttle AM, Moran MS, Rock SL, Vorhees CV. 2000. Preweaning treatment with methamphetamine induces increases in both corticosterone and ACTH in rats. Neurotoxicol Teratol 22:751-759.
248. Williams MT, Moran MS, Vorhees CV. 2003b. Refining the critical period for methamphetamine-induced spatial deficits in the Morris water maze. Psychopharmacology (Berl) 168:329-338.
249. Williams MT, Morford LL, Wood SL, Wallace TL, Fukumura M, Broening HW, Vorhees CV. 2003c. Developmental D-methamphetamine treatment selectively induces spatial navigation impairments in reference memory in the Morris water maze while sparing working memory. Synapse 48:138-148.
250. Williams MT, Vorhees CV, Boon F, Saber AJ, Cain DP. 2002. Methamphetamine exposure from postnatal day 11 to 20 causes impairments in both behavioral strategies and spatial learning in adult rats. Brain Res 958:312-321.
251. Won L, Bubula N, McCoy H, Heller A. 2001. Methamphetamine concentrations in fetal and maternal brain following prenatal exposure. Neurotoxicol Teratol 23:349-354.
252. Won L, Kontur PJ, Choi HK, Hoffmann PC, Heller B, Heller A. 1992. Acute and persistent effects of methamphetamine on developing monoaminergic neurons in reaggregate tissue culture. Brain Res 575:6-12.
253. Yamamoto Y, Yamamoto K, Abiru H, Fukui Y, Shiota K. 1995. Effects of methamphetamine on rat embryos cultured in vitro. Biol Neonate 68:33-38.
254. Yamamoto Y, Yamamoto K, Fukui Y, Kurishita A. 1992. Teratogenic effects of methamphetamine in mice. Nippon Hoigaku Zasshi 46:126-131.
255. Yamamoto Y, Yamamoto K, Hayase T. 1999. Effect of methamphetamine on male mice fertility. J Obstet Gynaecol Res 25:353-358.
256. Yamamoto Y, Yamamoto K, Hayase T, Fukui Y, Shiota K. 1998. Effects of amphetamine on rat embryos developing in vitro. Reprod Toxicol 12:133-137.
257. Yasuda M, Ariyuki F, Nishimura H. 1965. Effect of amphetamine on pregnancy in Icr-Jcl mice. Okajimas Folia Anat Jpn 41:227-231.
258. Zone SE, Buchi KF. 2002. Prenatal amphetamine use in Utah's newborn intensive care units. Pediatr Res 51:360A.